VIBRANT (NCT06164704) was a Phase 2 global, randomized, double-blind, placebo-controlled, parallel group clinical trial that evaluated the efficacy and safety of verekitug over 24 weeks in 81 adults ...
– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in ...
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also ...
Upstream Bio (UPB) lost ~12% in the premarket on Wednesday even after the company said that a mid-stage trial for its experimental asthma therapy, verekitug, succeeded, paving the way for the drug's ...
Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026. Upstream Bio, Inc. has initiated a global Phase 2 clinical ...
Upstream Bio Inc. (NASDAQ:UPB) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 8, Upstream Bio announced that the first patient had been dosed in a Phase 2 ...
– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided ...
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also ...
Detailed price information for Upstream Bio Inc (UPB-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results